Benzinga | Nov 10, 2021 06:13PM EST

Trevi Therapeutics, Inc. - Common Stock Q3 EPS $(0.34) Beats $(0.40) Estimate

Trevi Therapeutics, Inc. - Common Stock (NASDAQ:TRVI) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 15 percent increase over losses of $(0.40) per share from the same period last year.